The Kaplan-Meier survival analyses showed that HOXA5 expression is associated with the better overall survival and disease-free survival in NSCLC patients with the wild-type EGFR (Fig 6B and 6C; P = 0.0199 and 0.0345, respectively, log rank test). Here, HOXA5 is linked to non-small cell lung carcinoma.